HBIO Valuation
Harvard Bioscience Inc
$
0.500
- Overview
- Forecast
- Valuation
- Earnings
HBIO Relative Valuation
HBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HBIO is overvalued; if below, it's undervalued.
Historical Valuation
Harvard Bioscience Inc (HBIO) is now in the Fair zone, suggesting that its current forward PE ratio of 7.98 is considered Fairly compared with the five-year average of 24.83. The fair price of Harvard Bioscience Inc (HBIO) is between 0.34 to 2.17 according to relative valuation methord.
Relative Value
Fair Zone
0.34-2.17
Current Price：0.49
Fair
7.98
PE
1Y
3Y
5Y
Trailing
Forward
4.26
EV/EBITDA
Harvard Bioscience Inc. (HBIO) has a current EV/EBITDA of 4.26. The 5-year average EV/EBITDA is 14.46. The thresholds are as follows: Strongly Undervalued below 2.58, Undervalued between 2.58 and 8.52, Fairly Valued between 20.40 and 8.52, Overvalued between 20.40 and 26.34, and Strongly Overvalued above 26.34. The current Forward EV/EBITDA of 4.26 falls within the Undervalued range.
8.53
EV/EBIT
Harvard Bioscience Inc. (HBIO) has a current EV/EBIT of 8.53. The 5-year average EV/EBIT is 18.02. The thresholds are as follows: Strongly Undervalued below -5.37, Undervalued between -5.37 and 6.33, Fairly Valued between 29.72 and 6.33, Overvalued between 29.72 and 41.42, and Strongly Overvalued above 41.42. The current Forward EV/EBIT of 8.53 falls within the Historic Trend Line -Fairly Valued range.
0.24
PS
Harvard Bioscience Inc. (HBIO) has a current PS of 0.24. The 5-year average PS is 1.48. The thresholds are as follows: Strongly Undervalued below 0.17, Undervalued between 0.17 and 0.82, Fairly Valued between 2.13 and 0.82, Overvalued between 2.13 and 2.79, and Strongly Overvalued above 2.79. The current Forward PS of 0.24 falls within the Undervalued range.
4.28
P/OCF
Harvard Bioscience Inc. (HBIO) has a current P/OCF of 4.28. The 5-year average P/OCF is 23.36. The thresholds are as follows: Strongly Undervalued below -56.62, Undervalued between -56.62 and -16.63, Fairly Valued between 63.34 and -16.63, Overvalued between 63.34 and 103.33, and Strongly Overvalued above 103.33. The current Forward P/OCF of 4.28 falls within the Historic Trend Line -Fairly Valued range.
-0.88
P/FCF
Harvard Bioscience Inc. (HBIO) has a current P/FCF of -0.88. The 5-year average P/FCF is 17.72. The thresholds are as follows: Strongly Undervalued below -76.24, Undervalued between -76.24 and -29.26, Fairly Valued between 64.70 and -29.26, Overvalued between 64.70 and 111.68, and Strongly Overvalued above 111.68. The current Forward P/FCF of -0.88 falls within the Historic Trend Line -Fairly Valued range.
Harvard Bioscience Inc (HBIO) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 1.92 , the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 2.31, the current P/B ratio is about -100.00% higher. Harvard Bioscience Inc (HBIO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 2.38%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 2.18% , the current FCF yield is about -100.00% lower.
0.00
P/B
Median3y
1.92
Median5y
2.31
0.00
FCF Yield
Median3y
2.38
Median5y
2.18
Competitors Valuation Multiple
The average P/S ratio for HBIO's competitors is 1.01, providing a benchmark for relative valuation. Harvard Bioscience Inc Corp (HBIO) exhibits a P/S ratio of 0.24, which is -75.96% above the industry average. Given its robust revenue growth of -11.46%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of HBIO decreased by 83.25% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 23.10M to 20.45M.
The secondary factor is the Margin Expansion, contributed -11.92%to the performance.
Overall, the performance of HBIO in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
ALTS
ALT5 Sigma Corp
6.960
USD
+16.78%
SNAL
Snail Inc
1.050
USD
+5.00%
KPTI
Karyopharm Therapeutics Inc
4.450
USD
+10.70%
MCHX
Marchex Inc
1.806
USD
-11.03%
USAU
US Gold Corp
11.900
USD
-4.49%
DGICB
Donegal Group Inc
14.400
USD
+0.98%
CUE
Cue Biopharma Inc
0.810
USD
+2.53%
SPWH
Sportsmans Warehouse Holdings Inc
3.060
USD
-2.55%
CHCI
Comstock Holding Companies Inc
15.100
USD
+2.37%
JSPR
Jasper Therapeutics Inc
2.970
USD
+4.21%
FAQ
Is Harvard Bioscience Inc (HBIO) currently overvalued or undervalued?
Harvard Bioscience Inc (HBIO) is now in the Fair zone, suggesting that its current forward PE ratio of 7.98 is considered Fairly compared with the five-year average of 24.83. The fair price of Harvard Bioscience Inc (HBIO) is between 0.34 to 2.17 according to relative valuation methord.
What is Harvard Bioscience Inc (HBIO) fair value?
How does HBIO's valuation metrics compare to the industry average?
What is the current P/B ratio for Harvard Bioscience Inc (HBIO) as of Aug 13 2025?
What is the current FCF Yield for Harvard Bioscience Inc (HBIO) as of Aug 13 2025?
What is the current Forward P/E ratio for Harvard Bioscience Inc (HBIO) as of Aug 13 2025?